NCT01415518 - Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients | Biotech Hunter

Enrollment

581

Participants

Timeline

Start Date

September 1, 2011

Primary Completion Date

December 1, 2012

Study Completion Date

December 1, 2012

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Drug: Budesonide/formoterol (Symbicort Turbuhaler

budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily)

DRUG

Drug: ipratropium (AtroventTM)

ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily)

DRUG

theophylline SR

theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)

Trial Locations (21)

Research Site, Beijing

Research Site, Foshan

Research Site, Guangzhou

Research Site, Zhongshan

Research Site, Haikou

Research Site, Shijiazhuang

Research Site, Tangshan

Research Site, Zhengzhou

Research Site, Wuhan

Research Site, Changsha

Research Site, Nanjing

Research Site, Changchun

Research Site, Shenyang

Research Site, Qingdao

Research Site, Shanghai

Research Site, Tianjin

Research Site, Chengdu

Research Site, Chongqin

Research Site, Dalian

Research Site, Ha'er BING

Research Site, Hohhot